NCT02932280进行中（未招募）1 期
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 14
- 试验地点
- 9
- 主要终点
- the number of patients who have experienced Dose Limiting Toxicity
研究概览
简要总结
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis: Pathologic confirmation of solid tumor, including central nervous system tumor or lymphoma.
- •Recurrent or Refractory Disease for which no further effective standard treatment is available.
- •Patient must have failed at least one prior therapy.
- •All patients must have evaluable disease as defined as:
- •Solid tumors must have a lesion evaluable by RECIST criteria version 1.1;
- •Central nervous system tumors will be evaluated by RANO criteria.
- •Available tissue to perform protein and genomic analysis
- •Phase 1: ≥ 3 and ≤ 21 years of age at time of enrollment
- •Phase 2: ≥ 3 and ≤ 21 years of age at diagnosis
- •Body Surface Area requirements varied by dose level:
- •Dose Level BSA (m2)
- •Performance level:
- •Lansky score ≥ 60% (patients < 16 years of age)
- •Karnofsky score ≥ 60% (patients ≥ 16 years of age)
- •Cardiac Function: Patients must have a shortening fraction ≥ 27% or left ventricular ejection fraction ≥ 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA).
- •Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential ≤ 7 days before starting neratinib therapy.
- •Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product. Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product.
- •Written informed consent/assent prior to any study-specific procedures.
- •Patient must be able to swallow tablet or have existing gastrostomy feeding tube to enable administration of tablet.
- •Patients must have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering this study.
排除标准
- •Prior treatment within the following timeframes:
- •Systemic chemotherapy or biologic therapy ≤ 2 weeks or 5 half lives (t ½) of the agent used, whichever is shorter, prior to the start of neratinib
- •Radiation therapy outside the central nervous system ≤ 14 days prior to neratinib
- •Radiation to the central nervous system ≤ 12 weeks prior to initiation of neratinib
- •Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:
- •60 days from allogeneic SCT
- •Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD
- •Inadequate marrow function in Cohort 1:
- •Absolute neutrophil count < 1.0 x 10^9 /L
- •Platelets < 100 x 10^9 /L
- •Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
- •Total bilirubin > 1.5 X the upper limit of normal (ULN) for age
- •AST (SGOT) and ALT (SGPT) > 3 X ULN (unless attributed to disease involvement)
- •Serum creatinine > 1.5 X ULN for age or creatinine clearance ≤ 60mL/min/1.73m^2
- •Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days (or decreasing dose of corticosteroid) are eligible to participate in the study.) Patients with primary central nervous system tumors are eligible.
- •Clinically active cardiac disease, including prolonged QTc interval ≥ 481ms (i.e. ≥ grade 2)
- •Pregnant or breast-feeding women
- •Being actively treated for a concurrent malignancy with the exception of basal cell carcinoma or carcinoma in situ of the cervix.
- •Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, unexplained fever > 38.5°C (101.3°F) or psychiatric illness/social situation that would limit compliance with study requirements.
- •Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥ 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).
- •Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease
- •Known history of hepatitis C or known active hepatitis B infection
- •Known hypersensitivity to any component of the investigational product
研究组 & 干预措施
Neratinib
Experimental
There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
干预措施: Neratinib (Drug)
结局指标
主要结局
the number of patients who have experienced Dose Limiting Toxicity
时间窗: 1 year
NCI CTCAE Version 4.0.Definition of Hematologic Dose-Limiting Toxicity (solid tumor cohort only) Any hematologic toxicity as indicated: Febrile neutropenia defined as Grade 3 or 4 neutropenia with fever ≥ 38.5°C and /or infection requiring antibiotic or antifungal treatment Grade 4 neutropenia lasting \> 7 days Grade 4 thrombocytopenia lasting \> 7days Any drug-related adverse experience, regardless of grade, leading to a dose reduction of a study drug. Non-Hematologic Dose-Limiting Toxicities: Non-hematologic dose-limiting toxicity will be defined as any Grade 3, 4 or 5 nonhematologic toxicity with the specific exception of: Any grade diarrhea that occurs in the setting of poor compliance with supportive measures that last for \< 48 hours Any grade dehydration related to diarrhea that occurs in the setting of inadequate compliance to supportive care measures that last for \< 48 hours.
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
2 期
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerGastroEsophageal CancerGastric CancerNCT06109467H. Lee Moffitt Cancer Center and Research Institute8
已完成
1 期
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid TumorsNeoplasmsMalignant CarcinomaNCT00838539Puma Biotechnology, Inc.63
终止
1 期
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerBreast Inflammatory CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7NCT03101748M.D. Anderson Cancer Center34
已完成
2 期
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to ImatinibLeukemiaNCT00777036Bristol-Myers Squibb133
终止
1 期
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+Solid TumorNCT02593708Michelle Melisko6